X
 
 
 
 
 
 
 Home Page   My Sky Valley   Advertising   Contact Us   Privacy Policy   About Us   Terms of Use 
Register Here
Welcome

Log In
http://benjarongmonroe.com/menu/

Mon, September 24, 2018

"The #1 Read & Rated Sky Valley News Source
& Only Daily Paper in the Sky Valley!"
http://skyvalleychronicle.com/?t=advertising_rates

Cell Phones


RSS Feeds
Everett, WATemp: 57°FSky: overcastForecast...
SECTIONS
BREAKING NEWS
FEATURE NEWS
SNOHOMISH
MONROE
SULTAN
STARTUP
BARING
GOLD BAR
INDEX
SKYKOMISH
STEVENS PASS
GENERAL
VALLEY NEWS
OPINION &
EDITORIAL
VIDEOS
LEGAL NOTICES
CLASSIFIEDS
AUCTIONS
http://www.skyvalleychronicle.com/?template=advertising_rates

--

BREAKING NEWS

FDA gives go ahead to system designed to treat Obsessive Compulsive Disorder
August 18, 2018



(NATIONAL) – On Friday the U.S. Food and Drug Administration gave the okay for the marketing of a system called Brainsway Deep Transcranial Magnetic Stimulation for the treatment of obsessive compulsive disorder (OCD).

The FDA permitted marketing of the Brainsway device to Brainway Ltd.

“Transcranial magnetic stimulation has shown its potential to help patients suffering from depression and headaches,” said Carlos Peña, Ph.D., M.S., director of the Division of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health. “With today’s marketing authorization, patients with OCD who have not responded to traditional treatments now have another option.”

OCD is a common, chronic and long-lasting disorder in which a person has uncontrollable, reoccurring thoughts and behaviors that a person feels the urge to repeat over and over.

OCD is typically treated with medication, psychotherapy or a combination of the two. According to the National Institute of Mental Health, about 1 percent of U.S. adults had OCD in the past year. Although most patients with OCD respond to treatment, some patients continue to experience symptoms.

Transcranial magnetic stimulation (TMS) is a procedure that uses magnetic fields to stimulate nerve cells in the brain. The FDA permitted marketing of TMS as a treatment for major depression in 2008 and expanded the use to include TMS for treating pain associated with certain migraine headaches in 2013.

The FDA reviewed data from a randomized, multi-center study of 100 patients, of which 49 patients received treatment with the Brainsway device and 51 received treatment with a non-working (sham) device.

The results indicated that 38 percent of patients responded to the Brainsway device whereas 11 percent of patients responded when using the sham device.





BACK TO

HOME

More Headlines

BREAKING NEWS
Today's Cartoon
By Dan Rosandich
Near Port Orchard, WA the big bird was down but
not out
Snohomish, WA man riding a Harley, hit
by car on I-5
Wash State Patrol Trooper’s patrol car stolen as trooper responded to crashed vehicle
All Vashon-Maury Island beaches closed for shellfish harvesting

    More->



http://skyvalleychronicle.com/?t=advertising_rates


© 2008-2018 Sky Valley Media Group, LLC
www.skyvalleychronicle.com is owned and produced by
Sky Valley Media Group, LLC which is solely responsible for its content